PMID- 24269304
OWN - NLM
STAT- MEDLINE
DCOM- 20140131
LR  - 20131202
IS  - 2210-7762 (Print)
VI  - 206
IP  - 9-10
DP  - 2013 Sep-Oct
TI  - The advantage of using SNP array in clinical testing for hematological 
      malignancies--a comparative study of three genetic testing methods.
PG  - 317-26
LID - S2210-7762(13)00124-5 [pii]
LID - 10.1016/j.cancergen.2013.09.001 [doi]
AB  - Cytogenetic methods, including G-banded chromosome analysis and fluorescence in 
      situ hybridization (FISH) analysis, serve as a critical part of routine clinical 
      testing for hematological malignancies and provide important diagnostic and 
      prognostic information; however, the limitations of cytogenetic methods, 
      including the requirement for actively dividing cells and lower resolution of 
      G-banded chromosome analysis as well as the inability of both G-banded chromosome 
      analysis and FISH to detect copy number neutral loss of heterozygosity (CN-LOH), 
      can result in a failure to detect genomic abnormalities with diagnostic and 
      prognostic significance. Here, we compared the abnormality detection rate of 
      clinically requested testing (i.e., G-banded chromosome analysis and FISH) with 
      high-resolution oligo (i.e., array comparative genomic hybridization (aCGH)) and 
      single-nucleotide polymorphism (SNP)/oligo hybrid (i.e., SNP-CGH) arrays in a 
      series of patients, in an effort to assess the ability of newer technologies to 
      overcome these limitations. This series found the detection rate for SNP-CGH to 
      be 62.5% for myelodysplastic syndrome (MDS) cases and 72.7% for chronic 
      lymphocytic leukemia (CLL) cases, which are significantly higher than the 
      detection rates of aCGH (31.3% for MDS and 54.5% for CLL) and G-banding and/or 
      FISH (43.8% for MDS and 54.5% for CLL). This demonstrates the advantages of 
      combining SNP-CGH with conventional cytogenetics to provide comprehensive 
      clinical information by detecting clonality, large balanced rearrangements, copy 
      number aberrations, and CN-LOH.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Xu, Xinjie
AU  - Xu X
AD  - University of Wisconsin Cytogenetic Services, Wisconsin State Laboratory of 
      Hygiene, Madison, WI, USA; Department of Pediatrics, University of 
      Wisconsin-Madison, Madison, WI, USA.
FAU - Johnson, Eric B
AU  - Johnson EB
FAU - Leverton, Lisa
AU  - Leverton L
FAU - Arthur, Ashley
AU  - Arthur A
FAU - Watson, Quinn
AU  - Watson Q
FAU - Chang, Faye L
AU  - Chang FL
FAU - Raca, Gordana
AU  - Raca G
FAU - Laffin, Jennifer J
AU  - Laffin JJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20131024
PL  - United States
TA  - Cancer Genet
JT  - Cancer genetics
JID - 101539150
SB  - IM
MH  - Chromosome Aberrations
MH  - Chromosome Banding/methods
MH  - Comparative Genomic Hybridization/*methods
MH  - Early Detection of Cancer/*methods/statistics & numerical data
MH  - Hematologic Neoplasms/diagnosis/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - *Polymorphism, Single Nucleotide
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - SNP array
OT  - chronic lymphocytic leukemia
OT  - loss of heterozygosity
OT  - myelodysplastic syndrome
EDAT- 2013/11/26 06:00
MHDA- 2014/02/01 06:00
CRDT- 2013/11/26 06:00
PHST- 2012/11/15 00:00 [received]
PHST- 2013/09/09 00:00 [revised]
PHST- 2013/09/11 00:00 [accepted]
PHST- 2013/11/26 06:00 [entrez]
PHST- 2013/11/26 06:00 [pubmed]
PHST- 2014/02/01 06:00 [medline]
AID - S2210-7762(13)00124-5 [pii]
AID - 10.1016/j.cancergen.2013.09.001 [doi]
PST - ppublish
SO  - Cancer Genet. 2013 Sep-Oct;206(9-10):317-26. doi: 
      10.1016/j.cancergen.2013.09.001. Epub 2013 Oct 24.